Castle Biosciences Approved for Dual Listing on Nasdaq Texas

FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL."

"Castle was founded in Texas and remains deeply connected to the state's communities, talent and innovation ecosystem," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Our dual listing on Nasdaq Texas is an important reflection of those roots and our continued commitment to supporting Texas' growth as a hub for life sciences innovation while serving clinicians and patients through our portfolio of advanced testing solutions."